These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

238 related items for PubMed ID: 31904012

  • 1. Implantation and Monitoring by PET/CT of an Orthotopic Model of Human Pleural Mesothelioma in Athymic Mice.
    Colin DJ, Bejuy O, Germain S, Triponez F, Serre-Beinier V.
    J Vis Exp; 2019 Dec 21; (154):. PubMed ID: 31904012
    [Abstract] [Full Text] [Related]

  • 2. Biodistribution and Tumor Uptake of 67Ga-Nimotuzumab in a Malignant Pleural Mesothelioma Xenograft.
    Izquierdo-Sánchez V, Muñiz-Hernández S, Vázquez-Becerra H, Pacheco-Yepez J, Romero-Piña ME, Arrieta O, Medina LA.
    Molecules; 2018 Nov 29; 23(12):. PubMed ID: 30501113
    [Abstract] [Full Text] [Related]

  • 3. Characterization of hypoxia in malignant pleural mesothelioma with FMISO PET-CT.
    Francis RJ, Segard T, Morandeau L, Lee YC, Millward MJ, Segal A, Nowak AK.
    Lung Cancer; 2015 Oct 29; 90(1):55-60. PubMed ID: 26259878
    [Abstract] [Full Text] [Related]

  • 4. Metabolic response assessment with 18F-FDG-PET/CT is superior to modified RECIST for the evaluation of response to platinum-based doublet chemotherapy in malignant pleural mesothelioma.
    Kanemura S, Kuribayashi K, Funaguchi N, Shibata E, Mikami K, Doi H, Kitajima K, Hasegawa S, Nakano T.
    Eur J Radiol; 2017 Jan 29; 86():92-98. PubMed ID: 28027772
    [Abstract] [Full Text] [Related]

  • 5. Antitumor effect of novel anti-podoplanin antibody NZ-12 against malignant pleural mesothelioma in an orthotopic xenograft model.
    Abe S, Kaneko MK, Tsuchihashi Y, Izumi T, Ogasawara S, Okada N, Sato C, Tobiume M, Otsuka K, Miyamoto L, Tsuchiya K, Kawazoe K, Kato Y, Nishioka Y.
    Cancer Sci; 2016 Sep 29; 107(9):1198-205. PubMed ID: 27294401
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Whole-Body MRI: Comparison of Its Capability for TNM Staging of Malignant Pleural Mesothelioma With That of Coregistered PET/MRI, Integrated FDG PET/CT, and Conventional Imaging.
    Ohno Y, Yui M, Aoyagi K, Kishida Y, Seki S, Koyama H, Yoshikawa T.
    AJR Am J Roentgenol; 2019 Feb 29; 212(2):311-319. PubMed ID: 30512992
    [Abstract] [Full Text] [Related]

  • 10. Present and future roles of FDG-PET/CT imaging in the management of malignant pleural mesothelioma.
    Kitajima K, Doi H, Kuribayashi K.
    Jpn J Radiol; 2016 Aug 29; 34(8):537-47. PubMed ID: 27222020
    [Abstract] [Full Text] [Related]

  • 11. Prognostic significance of metabolic response by positron emission tomography after neoadjuvant chemotherapy for resectable malignant pleural mesothelioma.
    Tsutani Y, Takuwa T, Miyata Y, Fukuoka K, Hasegawa S, Nakano T, Okada M.
    Ann Oncol; 2013 Apr 29; 24(4):1005-10. PubMed ID: 23136224
    [Abstract] [Full Text] [Related]

  • 12. Positron Emission Tomography/Computed Tomography for the Pleural Staging of Malignant Pleural Mesothelioma: How Accurate Is It?
    Pinelli V, Roca E, Lucchini S, Laroumagne S, Loundou A, Dutau H, Maldonado F, Astoul P.
    Respiration; 2015 Apr 29; 89(6):558-64. PubMed ID: 25966972
    [Abstract] [Full Text] [Related]

  • 13. Experimental Model of Human Malignant Mesothelioma in Athymic Mice.
    Colin DJ, Cottet-Dumoulin D, Faivre A, Germain S, Triponez F, Serre-Beinier V.
    Int J Mol Sci; 2018 Jun 26; 19(7):. PubMed ID: 29949929
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Prognostic value of SUVmax on 18F-fluorodeoxyglucose PET/CT scan in patients with malignant pleural mesothelioma.
    Lim JH, Choi JY, Im Y, Yoo H, Jhun BW, Jeong BH, Park HY, Lee K, Kim H, Kwon OJ, Han J, Ahn MJ, Kim J, Um SW.
    PLoS One; 2020 Jun 26; 15(2):e0229299. PubMed ID: 32069313
    [Abstract] [Full Text] [Related]

  • 17. Clinical implications of 18F-fluorodeoxyglucose positron emission tomography/computed tomography at delayed phase for diagnosis and prognosis of malignant pleural mesothelioma.
    Abe Y, Tamura K, Sakata I, Ishida J, Ozeki Y, Tamura A, Uematsu K, Sakai H, Goya T, Kanazawa M, Machida K.
    Oncol Rep; 2012 Feb 26; 27(2):333-8. PubMed ID: 22024889
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. FDG PET/CT is useful for detecting infiltration to the port site in patients with malignant pleural mesothelioma.
    Kawaguchi K, Taniguchi T, Usami N, Fukui T, Ishiguro F, Nakamura S, Yokoi K.
    Gen Thorac Cardiovasc Surg; 2014 Mar 26; 62(3):157-62. PubMed ID: 24281913
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.